Evofem Biosciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

-- application allowed with broad method claims that are orange book-listable -- -- once issued, this will be evofem's fifth patent covering hormone-free "in the moment" contraceptive phexxi in the united states -- san diego , april 18, 2024 /prnewswire/ -- evofem biosciences, inc. (otcqb: evfm) announced today that the united states patent and trademark office (uspto) issued to the company a notice of allowance for patent application 17/823,020 entitled, "compositions and methods for enhancing the efficacy of contraceptive microbicides." this notice of allowance is expected to result in the issuance of a u.s. patent once administrative processes are completed.

-- third consecutive year of phexxi net sales growth  -- -- total operating expense reduced 64% from 2022 levels  -- -- sales and marketing expense as a percentage of net sales was 54% for the fourth quarter of 2023, the most favorable ratio since the phexxi launch -- san diego , march 27, 2024 /prnewswire/ -- the company behind phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator evofem biosciences, inc. (otcqb: evfm), today announced financial results for the fourth quarter and year ended december 31, 2023. highlights include: delivered $18.2 million of phexxi net product sales in 2023, an impressive increase compared to 2022 given the 73% reduction in field force and absence of growth capital in 2023.

-- new weight loss drugs like ozempic, wegovy and zepboundmay make oral birth control pills less effective at certain points -- san diego , march 7, 2024 /prnewswire/ -- use of glp-1 receptor agonists, or glp-1s, is skyrocketing in the united states, with more than nine million prescriptions for ozempic, wegovy, mounjaro, and similar diabetes and obesity drugs written during the last three months of 2022 alone.1 zepbound weekly prescriptions hit 25,000 in december 2023, just one month after it was approved to treat obesity.2 these drugs may make oral birth control pills less effective at certain points in the dosing schedule, making an unintended pregnancy more likely. eli lilly's mounjaro and zepbound, which contain the same compound, clearly instruct prescribers to "advise females using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.

Evofem delivers third consecutive year of phexxi net sales growth  total operating expense reduced more than 60% from 2022 levels  san diego , feb. 1, 2024 /prnewswire/ -- evofem biosciences, inc. (otcqb: evfm) today announced strong preliminary, unaudited results for fiscal 2023, including record net sales of phexxi® (lactic acid, citric acid, and potassium bitartrate), its hormone-free contraceptive gel, and the company's lowest total operating expenses since becoming a commercial stage company in 2020. achieved preliminary net product sales in the range of $18.1 to $18.3 million in 2023, an impressive increase compared to 2022 given the 73% reduction in field force and absence of growth capital in 2023.

New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of evofem biosciences, inc. (otc: evfm) to aditxt, inc. (nasdaqcm: adtx) in consideration of the issuance of a combination of common stock and preferred stock, and the assumption of certain senior indebtedness, having an aggregate amount of approximately $100 million. ksf is seeking to determine whether the merge.

Among the micro-cap stocks seeing an impressive surge today is Evofem (OTCMKTS: EVFM ). This little-known women's health company provides a range of innovative products aimed at improving women's sexual health.

Here's what you need to know about buying penny stocks on August 5th? The post Penny Stocks to Buy Premarket on August 5th?

Evofem Biosciences, Inc. (NASDAQ:EVFM ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Amy Raskopf - Vice President-Investor Relations Saundra Pelletier - Chief Executive Officer, President and Executive Director Jay File - Chief Financial Officer Katherine Atkinson - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Yale Jen - Laidlaw and Company Stacy Lee - Stifel Ram Selvaraju - H.C. Wainwright Operator Good afternoon.

-- Conference Call Scheduled for 5:00 p.m. ET -- SAN DIEGO , July 28, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2022 as follows: Date: Thursday, August 4, 2022 Time: 5:00 pm.

Short squeeze penny stocks to watch right now. The post Penny Stocks To Buy?

Here's what you need to know about trading penny stocks on July 12th The post What to Know About Buying Penny Stocks on July 12th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check these penny stocks out for your watchlist right now The post Best Penny Stocks to Buy Right Now? 3 to Watch  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

A huge battle playing out between the bulls and bears … so much rests on Q2 earnings … get ready for a month of important data releases The markets are setting up for a dramatic breakout – the question is: “In which direction?” Either the bears are overly pessimistic, and the next few months will.

Fintel has ranked Evofem Biosciences as the next top gamma squeeze. Will Meade noticed.

What you need to know about trading penny stocks this month The post July Penny Stocks Buying Guide, 3 Things to Know appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.